FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

被引：14

作者：

Nakaigawa, Noboru ^{[1
]}

Kondo, Keiichi ^{[1
]}

Kaneta, Tomohiro ^{[2
]}

Tateishi, Ukihide ^{[2
]}

Minamimoto, Ryogo ^{[2
]}

Namura, Kazuhiro ^{[1
]}

Ueno, Daiki ^{[1
]}

Kobayashi, Kazuki ^{[3
]}

Kishida, Takeshi ^{[4
]}

Ikeda, Ichiro ^{[5
]}

Hasumi, Hisashi ^{[1
]}

Makiyama, Kazuhide ^{[1
]}

Hayashi, Narihiko ^{[1
]}

Osaka, Kimito ^{[1
]}

Muraoka, Kentaro ^{[1
]}

Izumi, Koji ^{[1
]}

Kawahara, Takashi ^{[1
]}

Teranishi, Jun-ichi ^{[1
]}

Miyoshi, Yasuhide ^{[1
]}

Yumura, Yasushi ^{[1
]}

Uemura, Hiroji ^{[1
]}

Inoue, Tomio ^{[2
]}

Yao, Masahiro ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Urol, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan

[2] Yokohama City Univ, Grad Sch Med, Dept Radiol, Yokohama, Kanagawa, Japan

[3] Yokosuka Kyosai Hosp, Dept Urol, Yokosuka, Kanagawa, Japan

[4] Kanagawa Canc Ctr, Dept Urol, Yokohama, Kanagawa, Japan

[5] Yokohama Minami Kyosai Hosp, Dept Urol, Yokohama, Kanagawa, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2018年 / 81卷 / 04期

关键词：

Renal cell carcinoma; FDG PET/CT; Prognosis; Molecular targeted therapy; POSITRON-EMISSION-TOMOGRAPHY; INTERFERON-ALPHA; DISTANT METASTASES; EVEROLIMUS; SUNITINIB; SURVEILLANCE; SORAFENIB; BIOMARKER;

D O I：

10.1007/s00280-018-3542-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated prospectively whether F-18-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular targeted therapies. Between 2009 and 2016, 81 patients who had received single molecular targeted therapies (43 sorafenib, 27 sunitinib, 8 temsirolimus and others) and were scheduled for second line molecular targeted therapies for advanced RCC were enrolled in this prospective study. FDG PET/CT was performed after first line molecular targeted therapies, the max SUVmax (highest standardized uptake value for each patient) recorded, and its association with OS compared with those of known risk factors. The median follow-up was 15.4 months (range 0.9-97.4 months). The max SUVmax of the 81 subjects ranged from undetectable to 23.0 (median 7.1). Patients with high max SUVmax had a poor prognosis and multivariate analysis with established risk factors showed that it was an independent predictor of survival (p < 0.001; hazard ratio 1.156; 95% confidence interval 1.080-1.239). Subclassification of patients by max SUVmax showed that the median OS of patients with max SUVmax < 7.0 (39), 7.0-12.0 (30), and ae 12.0 (12) were 32.8, 15.2, and 6.0 months, respectively. These differences are statistically significant (< 7.0 versus 7.0-12.0: p = 0.0333, 7.0-12.0 versus ae 12.0: p = 0.0235). The max SUVmax by FDG PET/CT of patients with RCC evaluated after their first molecular targeted therapy predicts OS. FDG PET/CT is a useful "imaging biomarker" for patients with advanced RCC planning sequential molecular targeted therapies.

引用

页码：739 / 744

页数：6

共 30 条

[1] Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases:: a comparison with CT [J].

Aide, N ;

Cappele, O ;

Bottet, P ;

Bensadoun, H ;

Regeasse, A ;

Comoz, F ;

Sobrio, F ;

Bouvard, G ;

Agostini, D .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (09) :1236-1245

[2] FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer [J].

Chen, James L. ;

Appelbaum, Daniel E. ;

Kocherginsky, Masha ;

Cowey, Charles L. ;

Rathmell, Wendy Kimryn ;

McDermott, David F. ;

Stadler, Walter M. .

CANCER MEDICINE, 2013, 2 (04) :545-552

[3] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[4] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Porta, C. ;

Schmidinger, M. ;

Algaba, F. ;

Patard, J. J. ;

Khoo, V. ;

Eisen, T. ;

Horwich, A. .

ANNALS OF ONCOLOGY, 2014, 25 :49-56

[5] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[6]

Ferda J, 2013, ANTICANCER RES, V33, P2665

[7] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[8] One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival [J].

Ito, Hiroki ;

Kondo, Keiichi ;

Kawahara, Takashi ;

Kaneta, Tomohiro ;

Tateishi, Ukihide ;

Ueno, Daiki ;

Namura, Kazuhiro ;

Kobayashi, Kazuki ;

Miyoshi, Yasuhide ;

Yumura, Yasushi ;

Makiyama, Kazuhide ;

Hayashi, Narihiko ;

Hasumi, Hisashi ;

Osaka, Kimito ;

Yokomizo, Yumiko ;

Teranishi, Jun-ichi ;

Hattori, Yusuke ;

Inoue, Tomio ;

Uemura, Hiroji ;

Yao, Masahiro ;

Nakaigawa, Noboru .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) :855-861

[9] Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease [J].

Janzen, NK ;

Kim, HL ;

Figlin, RA ;

Belldegrun, AS .

UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (04) :843-+

[10] Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma [J].

Kang, DE ;

White, RL ;

Zuger, JH ;

Sasser, HC ;

Teigland, CM .

JOURNAL OF UROLOGY, 2004, 171 (05) :1806-1809

← 1 2 3 →